Business
Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.comRedondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a pharmaceutical development company focused on heart health, is developing therapies to address the intertwined effects of these three conditions with the hope of improving outcomes for COVID-19 patients.It is no secret that people with underlying health conditions are the most vulnerable potential COVID-19 patients. Prominent among these hazardous underlying conditions is heart disease. According to the Centers for Disease Control, patients with heart failure, coronary artery disease, and other heart conditions are particularly at risk for severe illness from the virus.The connection between COVID-19 and the heart is, along with many other aspects of this novel disease, slowly coming into focus. There is mounting evidence that COVID-19 may also produce heart injury in patients, and excessive inflammation (sometimes resulting in a fatal cytokine storm) may be the culprit. This scientific article lays out the case pretty clearly: treating heart inflammation is a key to avoiding catastrophic results.Cardiol Therapeutics, already focused on developing therapies for heart conditions, is forging ahead in this area. Cardiol filed a new patent application covering the use of cannabidiol (CBD) to improve the outcome of patients with COVID-19. The company has already planned to study CBD as a primary active in the treatment for heart failure and acute myocarditis. With all of the evidence surrounding heart disease and negative COVID-19 outcomes, Cardiol is naturally progressing its research to determine whether CBD can help a) improve outcomes for patients with pre-existing heart conditions or risk factor for heart disease, and b) decrease the occurrence of cardiovascular complications in such patients.Inflammation is the EnemyChronic heart failure (HF) is common, with an estimated six million adults suffering from the disease in Canada and the United States. Approximately 50% of patients with HF have a condition kno...